Suppr超能文献

心肺运动试验在接受β受体阻滞剂治疗的心力衰竭患者中的预后价值。

The prognostic value of the cardiopulmonary exercise test in patients with heart failure who have been treated with beta-blockers.

作者信息

Dufay-Bougon Clémentine, Belin Annette, Dahdouh Ziad Said, Barthelemy Sophie, Mabire Jean-Paul, Sabatier Rémi, Milliez Paul, Grollier Gilles

机构信息

Department of Cardiology, CHU de Caen, France.

出版信息

Turk Kardiyol Dern Ars. 2013 Mar;41(2):105-12. doi: 10.5543/tkda.2013.87404.

Abstract

OBJECTIVES

The prevalence of chronic heart failure and a reduced ejection fraction (CHF-REF) has increased over the last decade. The cardiopulmonary exercise test (CPET) is an established tool for managing these patients. For patients who are administered beta-blockers, its predictive value is debated. The aim of this study was to assess the prognostic values of several parameters in patients with CHF-REF who were on beta-blockers.

STUDY DESIGN

390 patients with CHF-REF underwent CPET after cardiac rehabilitation and were followed for two years.

RESULTS

The primary endpoints were all-cause mortality, cardiac-related mortality and major cardiovascular events (hospitalization for HF, heart transplantation and acute coronary syndrome or arrhythmia). The mean beta-blockers dosage was 68.9% of the target dose. The two-year mortality rate was 13%, while the mean age of the population was 57.1 years. In addition, most of the patients were men (85.5% vs. 14.5%). The resting LVEF was 35.7 ± 9.4 and the maximal oxygen uptake (peak VO₂) was 19.5 ml/kg/min. The peak VO₂, VE/VCO₂ slope and circulatory power were significant predictors of risk. The prognosis was better when the initial linear VE/VCO₂ slope was lower than 30, and the final steeper VE/VCO₂ slope was lower than 32. There was no difference between the two slopes. The oxygen uptake efficiency slope, oxygen uptake, heart rate recovery, VE/VCO₂/VO₂ index and ventilatory threshold had no prognostic value.

CONCLUSION

The peak VO₂, circulatory power and VE/VCO₂ slope were prognostic indicators for patients with CHF-REF who were on beta-blockers.

摘要

目的

在过去十年中,慢性心力衰竭伴射血分数降低(CHF-REF)的患病率有所上升。心肺运动试验(CPET)是管理这些患者的既定工具。对于接受β受体阻滞剂治疗的患者,其预测价值存在争议。本研究的目的是评估接受β受体阻滞剂治疗的CHF-REF患者中几个参数的预后价值。

研究设计

390例CHF-REF患者在心脏康复后接受了CPET,并随访了两年。

结果

主要终点为全因死亡率、心脏相关死亡率和主要心血管事件(因心力衰竭住院、心脏移植以及急性冠状动脉综合征或心律失常)。β受体阻滞剂的平均剂量为目标剂量的68.9%。两年死亡率为13%,而人群的平均年龄为57.1岁。此外,大多数患者为男性(85.5%对14.5%)。静息左心室射血分数(LVEF)为35.7±9.4,最大摄氧量(峰值VO₂)为19.5 ml/kg/min。峰值VO₂、VE/VCO₂斜率和循环功率是风险的重要预测指标。当初始线性VE/VCO₂斜率低于30且最终较陡的VE/VCO₂斜率低于32时,预后较好。两个斜率之间无差异。摄氧效率斜率、摄氧量、心率恢复、VE/VCO₂/VO₂指数和通气阈值无预后价值。

结论

峰值VO₂、循环功率和VE/VCO₂斜率是接受β受体阻滞剂治疗的CHF-REF患者的预后指标。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验